U.S. Oil and Gas Stock News

NasdaqGS:VICR
NasdaqGS:VICRElectrical

Vicor IP Rulings Highlight Shift Toward High Margin Licensing Model

Vicor (NasdaqGS:VICR) reports a surge in high margin IP licensing and royalty revenue following favorable International Trade Commission (ITC) rulings. The ITC outcomes support Vicor's efforts to monetize its power conversion intellectual property across a broader set of industry partners. These developments point to a potential inflection in Vicor's business model, with licensing now playing a larger role alongside product sales. For you as an investor, the key point is that Vicor is known...
NasdaqGM:INOD
NasdaqGM:INODProfessional Services

Innodata Palantir AI Deal Tests Valuation And Growth Expectations

Innodata (NasdaqGM:INOD) has entered into a partnership with Palantir to provide specialized data engineering and annotation for advanced AI projects. The collaboration focuses on complex, real world use cases, including video annotation and multimodal generative AI workflows for performance analytics in ride event analysis. The agreement positions Innodata as a key data partner for high stakes AI deployments where quality, security and domain specific workflows are central...
OTCPK:ACGP
OTCPK:ACGPCapital Markets

Associated Capital Group (ACGP) One Off Gain Clouds FY 2025 Earnings Growth Story

Associated Capital Group (ACGP) has wrapped up FY 2025 with fourth quarter revenue of US$20.1 million and basic EPS of US$0.54. Trailing 12 month revenue sits at US$26.9 million and EPS at US$2.52, alongside earnings growth of 19.5% over the past year. Over recent periods the company has seen quarterly revenue move from US$5.2 million in Q4 2024 to US$2.1 million in Q1 2025, US$2.2 million in Q2, US$2.5 million in Q3 and then step up to US$20.1 million in Q4. Quarterly EPS has run from...
NasdaqGS:FTDR
NasdaqGS:FTDRConsumer Services

Curreen Capital Spotlights Frontdoor Cash Use And Valuation Setup

Curreen Capital has highlighted Frontdoor (NasdaqGS:FTDR) as a key holding in its latest investor letter. The firm pointed to Frontdoor's 2025 results and its use of free cash flow for organic growth, debt reduction, share repurchases, and targeted acquisitions. This update provides fresh insight into how Frontdoor is allocating capital across its business and balance sheet. Frontdoor runs a home services platform, which typically includes subscription style offerings for home repair and...
NYSE:PFGC
NYSE:PFGCConsumer Retailing

Performance Food Group (PFGC) Margin Pressure Tests Bullish Growth Narratives In Q2 2026

Performance Food Group (PFGC) has put fresh numbers on the table for Q2 2026, reporting revenue of about US$16.4b and basic EPS of US$0.40 alongside net income of US$61.7m. The company has seen quarterly revenue move from roughly US$15.6b in Q2 2025 to US$16.4b this quarter, with basic EPS over that stretch ranging from US$0.27 to US$0.85 and trailing twelve month EPS at US$2.22. This sets a clear earnings backdrop for today’s release. With trailing net margins still tight, the latest results...
NasdaqGS:EZPW
NasdaqGS:EZPWConsumer Finance

EZCORP (EZPW) Margin Improvement Reinforces Bullish Earnings Narratives In Q1 2026

EZCORP (EZPW) opened Q1 2026 with revenue of US$382.0 million and basic EPS of US$0.72, setting a clear marker against a trailing twelve month EPS of US$2.08 and total revenue of about US$1.3 billion. Over the past year, the company has seen quarterly revenue move from US$320.2 million in Q1 2025 to US$382.0 million in Q1 2026, while quarterly EPS shifted from US$0.57 to US$0.72, with trailing net income reaching US$122.9 million. Trailing net margins are now at 9.2% compared with 7.2% a year...
NYSE:MOD
NYSE:MODBuilding

Modine Manufacturing (MOD) Quarterly Loss Challenges High Growth And Premium Valuation Narratives

Modine Manufacturing (MOD) has posted a mixed Q3 2026 update, with revenue at US$805 million and a basic EPS loss of US$0.90, alongside trailing twelve month basic EPS of US$1.86 on revenue of US$2.9 billion. The company has seen quarterly revenue move from US$616.8 million and EPS of US$0.78 in Q3 2025 to US$805 million and a loss in Q3 2026. Over the same period, trailing twelve month revenue has ranged between US$2.5 billion and US$2.9 billion, with EPS between US$1.86 and US$3.57,...
NasdaqGS:PLUS
NasdaqGS:PLUSElectronic

EPlus (PLUS) Earnings Quality Concerns Challenge Bullish Narrative After 53.7% Profit Surge

ePlus (PLUS) has just reported Q3 2026 results with revenue of US$614.8 million and basic EPS of US$1.28, set against trailing twelve month revenue of about US$2.4 billion and EPS of US$5.27 that came alongside a 53.7% rise in earnings over the past year. The company has seen revenue move from US$498.1 million and EPS of US$0.96 in Q4 2025 to between roughly US$608.8 million and US$637.3 million, with EPS ranging from US$1.03 to US$1.45 across the first three quarters of 2026. With net margin...
NasdaqGS:SIGI
NasdaqGS:SIGIInsurance

Selective Insurance Group Insider Buying Aligns With Tighter Board Governance

Selective Insurance Group director increased a personal stake in the company through a recent share purchase. The transaction coincides with board approved amendments to the company’s bylaws on director eligibility and leadership responsibilities. The combination of insider buying and governance updates is drawing attention from existing shareholders and potential investors. Selective Insurance Group, traded as NasdaqGS:SIGI, is drawing fresh interest after this insider move at a share...
NasdaqCM:PLYX
NasdaqCM:PLYXPharmaceuticals

Polaryx Therapeutics (PLYX) Valuation Check After Sharp Single Day Share Price Decline

Polaryx Therapeutics (PLYX) has drawn investor attention after a sharp 28.9% single day share price decline, with the stock closing at US$16. This move comes against a year to date return of negative 54.3%. See our latest analysis for Polaryx Therapeutics. The sharp 28.9% single day share price return decline and the year to date share price return of 54.3% point to fading momentum, suggesting that recent moves reflect shifting risk perception more than steady longer term sentiment. If...
OTCPK:SGMO
OTCPK:SGMOBiotechs

Assessing Sangamo Therapeutics (SGMO) Valuation After New Fabry Data Financing Move And Leadership Changes

Clinical and financing moves put Sangamo Therapeutics (SGMO) in focus Sangamo Therapeutics (SGMO) moved into the spotlight after releasing detailed Phase 1/2 STAAR study data for its Fabry gene therapy candidate, alongside a US$25 million follow on equity offering and a change in its finance leadership. See our latest analysis for Sangamo Therapeutics. Against this backdrop of clinical data, financing and leadership change, Sangamo Therapeutics’ share price has been under pressure, with a 30...
NYSE:DAVA
NYSE:DAVAIT

Endava (DAVA) Is Down 15.6% After Conservative Guidance Highlights Slower Growth And Cautious Demand – Has The Bull Case Changed?

In recent days, Endava reiterated its emphasis on complex digital transformation projects while issuing conservative guidance that reflects slower revenue growth and cautious enterprise demand. This shift in tone has prompted a more reserved stance from analysts, who are reassessing the company’s risk profile and longer-term growth narrative. With conservative guidance underscoring slower revenue growth, we’ll now examine how this development reshapes Endava’s broader investment narrative...
NYSEAM:GROY
NYSEAM:GROYMetals and Mining

Is Gold Royalty (GROY) Offering Value After A 192% One Year Share Price Jump

If you are trying to figure out whether Gold Royalty is genuinely good value or just riding hype, starting with a clear view of its current valuation is essential. Gold Royalty's share price, last seen at US$4.35, has had mixed short term moves, with a 10.3% decline over the last 7 days, a 4.3% gain over 30 days, and returns of 6.6% year to date and 191.9% over the past year. Recent commentary around Gold Royalty has focused on its position within the gold royalty space and investor interest...
OTCPK:BSEM
OTCPK:BSEMPharmaceuticals

Is It Time To Revisit BioStem Technologies (OTCPK:BSEM) After Its Recent Share Price Swings?

If you are trying to work out whether BioStem Technologies at around US$5.95 is attractively priced or not, you are in the right place. The share price has been volatile recently, with a 51.3% gain over the last 30 days, a 22.6% decline over the last week, a 52.3% gain year to date, and a 67.1% decline over the last year, alongside very large gains over 3 and 5 years. These sharp moves have come as investors react to ongoing developments around the company and its position in the...
NasdaqGS:FWRG
NasdaqGS:FWRGHospitality

A Look At First Watch Restaurant Group (FWRG) Valuation After Recent Share Price Gains

What the recent price move might mean for First Watch Restaurant Group (FWRG) First Watch Restaurant Group (FWRG) has drawn fresh attention after a recent share price move, with the stock closing at $17.24 and sitting on a month return of about 7% and year to date gain near 12%. See our latest analysis for First Watch Restaurant Group. Against that latest move, the 7 day share price return of 6.49% and 30 day share price return of 7.28% sit alongside a year to date share price return of...